Alpha cognition inc. common stock ACOG.US Overview
ACOG AI Analysis & Strategy
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
ACOG Current Performance
-2.06%
Alpha cognition inc. common stock
0.84%
Avg of Sector
0.83%
S&P500
ACOG Key Information
ACOG Financial Forecast
Unit : USD
ACOG Earnings Table
ACOG Profile
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.